The Genome Austria Tissue Bank (GATiB)Asslaber M.a · Abuja P.M.a · Stark K.a, f · Eder J.f · Gottweis H.g · Trauner M.b · Samonigg H.c · Mischinger H.J.d · Schippinger W.c · Berghold A.e · Denk H.a · Zatloukal K.a
aInstitute of Pathology, bDepartment of Medicine, Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, cDivision of Oncology, Department of Internal Medicine, dDivision of General Surgery, Department of Surgery, and eInstitute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, and fFaculty of Computer Sciences, and gDepartment of Political Science, University of Vienna, Vienna, Austria
Kurt Zatloukal, MD
Institute of Pathology, Medical University of Graz
AT–8036 Graz (Austria)
Tel. +43 316 380 4404, Fax +43 316 384 329, E-Mail firstname.lastname@example.org
Do you have an account?
In the context of the Austrian Genome Program, a tissue bank is being established (Genome Austria Tissue Bank, GATiB) which is based on a collection of diseased and corresponding normal tissues representing a great variety of diseases at their natural frequency of occurrence from a non-selected Central European population of more than 700,000 patients. Major emphasis is put on annotation of archival tissue with comprehensive clinical data, including follow-up data. A specific IT infrastructure supports sample annotation, tracking of sample usage as well as sample and data storage. Innovative data protection tools were developed which prevent sample donor re-identification, particularly if detailed medical and genetic data are combined. For quality control of old archival tissues, new techniques were established to check RNA quality and antigen stability. Since 2003, GATiB has changed from a population-based tissue bank to a disease-focused biobank comprising major cancers such as colon, breast, liver, as well as metabolic liver diseases and organs affected by the metabolic syndrome. Prospectively collected tissues are associated with blood samples and detailed data on the sample donor’s disease, lifestyle and environmental exposure, following standard operating procedures. Major emphasis is also placed on ethical, legal and social issues (ELSI) related to biobanks. A specific research project and an international advisory board ensure the proper embedding of GATiB in society and facilitate international networking.
© 2007 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.